Literature DB >> 1874564

Induction of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice.

J Törnell1, L Rymo, O G Isaksson.   

Abstract

To develop transgenic mice, a mouse metallothionein promoter-human growth hormone (Mt-hGH) gene fragment was injected into the pronucleus of C57BI x DBA/2J F2 one-cell embryos. Six founder animals grew larger (1.3-2.2 times) than littermate controls and had higher levels of hGH in plasma (4.6-279 mU/l). At 27-43 weeks of age, 3 of the 4 female transgenic founders developed malignant papillary adenocarcinomas of mammary origin. One of the male transgenic founders was successfully mated and 2 of 3 female transgenic offspring developed mammary tumors. Forty-two female mice with the same genetic background as the transgenic animals and older than 43 weeks served as controls. No palpable tumor was found in this group. Five of the control animals were killed and examined histologically, revealing only normal mammary tissue. Earlier studies have shown that GH is important for growth and development of the mammary gland. Our study suggests that markedly elevated endogenous levels of GH cause mammary carcinoma in a specific strain of transgenic mice. The present animal model might be useful for studying molecular mechanisms that are involved in the development of hormonally induced mammary tumors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1874564     DOI: 10.1002/ijc.2910490121

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

Review 1.  The role of circulating IGF-I: lessons from human and animal models.

Authors:  Shoshana Yakar; Yiping Wu; Jennifer Setser; Clifford J Rosen
Journal:  Endocrine       Date:  2002-12       Impact factor: 3.633

2.  Thyroid cancer is the most common cancer associated with acromegaly.

Authors:  Bennur Esen Gullu; Ozlem Celik; Nurperi Gazioglu; Pinar Kadioglu
Journal:  Pituitary       Date:  2010-09       Impact factor: 4.107

Review 3.  Growth hormone in the tumor microenvironment.

Authors:  Vera Chesnokova; Shlomo Melmed
Journal:  Arch Endocrinol Metab       Date:  2019 Nov-Dec       Impact factor: 2.309

4.  Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice.

Authors:  H Wennbo; M Gebre-Medhin; A Gritli-Linde; C Ohlsson; O G Isaksson; J Törnell
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

Review 5.  Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.

Authors:  David L Kleinberg; Teresa L Wood; Priscilla A Furth; Adrian V Lee
Journal:  Endocr Rev       Date:  2008-12-15       Impact factor: 19.871

Review 6.  Historical perspectives of prolactin and growth hormone as mammogens, lactogens and galactagogues--agog for the future!

Authors:  Josephine F Trott; Barbara K Vonderhaar; Russell C Hovey
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-19       Impact factor: 2.673

7.  Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer.

Authors:  K Sakamoto; A A Triplett; L A Schuler; K-U Wagner
Journal:  Oncogene       Date:  2010-07-19       Impact factor: 9.867

Review 8.  Transgenic models to study actions of prolactin in mammary neoplasia.

Authors:  Lisa M Arendt; Linda A Schuler
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-25       Impact factor: 2.673

Review 9.  The role of endocrine insulin-like growth factor-I and insulin in breast cancer.

Authors:  Danielle Lann; Derek LeRoith
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-22       Impact factor: 2.673

10.  The insulin-like growth factor system and its receptors: A potential novel anticancer target.

Authors:  Colin R Lindsay; Tr Jeffry Evans
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.